米托蒽醌毫微球在裸鼠人肝癌模型体内的靶向性研究  

STUDY ON TARGETING EFFECT OF ~3H-MITOXANTRONE NANOSPHERES ON HUMAN HEPATOCELLULAR CARCINOMA(HHC)MODEL IN NUDE MICE

作　　者：张志荣[1] 廖工铁[1] 侯世祥[1] 白绍槐[2] 张旋波[2] 

机构地区：[1]华西医科大学药学院,成都610041 [2]华西医科大学实验动物中心

出　　处：《华西药学杂志》1993年第4期191-195,共5页West China Journal of Pharmaceutical Sciences

基　　金：国家自然科学基金

摘　　要：米托蒽醌（ｍｅｔｏｘａｎｔｒｏｎｅ，ＤＨＡＱ）是近年合成的抗肿瘤新药〔１〕。国内外主要用于治疗白血病和乳腺癌，近年国外的临床研究证明其抗原性肝癌的效果亦较好，有开发价值〔２，３〕。有研究ＤＨＡＱ的水针剂静脉注射后虽有约４５％集中于肝脏，且心脏毒性较阿霉素低，但由于其浓集于肝脏的速度慢（约需６ｈ），故仍存在较大的毒性〔４，５〕。毫微球是一种新型药物载体。The distribution of ~3H-mitoxantrone polybutyanoacrylate nano-spheres (~3H-DHAQ-PBC A-NS) in theviscera, muscle and tumors of humanhepatocellular. carcinoma (HHC) model innude mice has been studied with liquidscintillation counting technique. Theresult showed that the ~3H-DHAQ-PBCA-NS have remarkable liver targetingeffect. The radioactivity in liver wasfounu to be 71.31±110.49% of total cpmfound in nude mice. The radioactivityin the liver tumor was higher than thatin liver tissue, and the radioactivity inarmpit tumor was higher than that inthe armpit muscle tissue, but the differ-ence is not significant statistically. Thisprovides an ideal preparation for theDHAQ administration.

关 键 词：米托蒽醌 毫微球 肝癌 靶向给药系 

分 类 号：R969.3[医药卫生—药理学]